STAT News
Virginia Governor Abigail Spanberger has exercised her veto power against significant legislation aimed at forming an advisory panel designed to mitigate the escalating costs of prescription drugs. This decision marks a notable halt to efforts by lawmakers across the nation striving to confront the increasing financial burden associated with pharmaceuticals.
The proposed Virginia advisory panel was distinct from affordability boards established in other states, as it intended to utilize Medicare as a pricing benchmark. Each year, rather than initiating a new process to identify high-cost drugs, the panel would have focused on the same medications selected by Medicare for price negotiations. Furthermore, it would have established upper payment limits, thereby creating a ceiling on permissible expenditures.
By adopting this approach, Virginia would have outpaced the initiatives of other states, which are at various stages of forming affordability boards. Among the nine other states with existing boards, none is targeting the same drugs nominated by Medicare annually, and only four possess the authority to implement upper payment limits.
Share this story